Elecoglipron for weight management in Asian adults with obesity or overweight
Tests elecoglipron against placebo for weight management in Asian adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Key facts
- Where
- Davao City, Iloilo City, and Manila, PhilippinesSee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight, with or without type 2 diabetes. It compares elecoglipron with placebo alongside diet and exercise for weight management.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Body mass index (BMI) of 28 kg/m^2 or higher, or 24 kg/m^2 to less than 28 kg/m^2 with at least 1 weight-related comorbidity. People with type 2 diabetes need HbA1c from 6.5% (48 mmol/mol) to less than 10.0% (86 mmol/mol).
- Earlier treatment
- At least 1 self-reported unsuccessful dietary effort to lose body weight. Stable body weight for 90 days before screening (± 5% change).
- Biomarker or test result
- HbA1c from 6.5% (48 mmol/mol) to less than 10.0% (86 mmol/mol) at screening, for people with type 2 diabetes.
Main reasons for not taking part
- Type 1 diabetes
- HbA1c of 10% (86 mmol/mol) or higher at screening
- Treatment for diabetic retinopathy or macular edema, now or expected
- More than one episode of severe hypoglycemia in the 180 days before screening, or hypoglycemia unawareness
- History of acute or chronic pancreatitis, or of medullary thyroid cancer or multiple endocrine neoplasia type 2 (also in first-degree relatives)
Read by machine on 10 November 2026.
Where in Philippines
- Davao CityDavao City, PhilippinesNot yet recruiting
- Iloilo CityIloilo City, PhilippinesNot yet recruiting
- ManilaManila, PhilippinesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07775404
- Record updated
- 9 November 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.Read full original descriptionShow less
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.
Inclusion: Adult participant aged 18 years or older at the time of informed consent; Body mass index (BMI) at screening of:; 28 kg/m\^2 or higher, or; 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity; Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change); History of at least 1 self-reported unsuccessful dietary effort to lose body weight; Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis; History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2; Any of the following medical history, laboratory values, or complications related to diabetes:; HbA1c ≥ 10% (86 mmol/mol) at the screening visit; T1DM.